Webinar
PDCs have gained extensive attention as they are being proven successful in treating cancers recently with their superior target-specific delivery. PDCs combine peptides and linker-toxins,…
PDCs have gained extensive attention as they are being proven successful in treating cancers recently with their superior target-specific delivery. PDCs combine peptides and linker-toxins, their development and manufacturing require comprehensive synthetic chemistry, process development, analytical method development, and manufacturing capabilities for both highly potent small molecules and peptides, which often bring technical challenges, especially during scale-up. Here we discuss how we overcome challenges and demonstrate opportunities through case studies.
Keep reading
Process mass intensity (PMI) is one of the most important metrics in sustainable manufacturing. It measures the total mass of raw materials required to produce a given mass of product. In…
As GLP-1 receptor agonists continue to redefine treatment for metabolic diseases, drug developers are racing to bring new and more complex therapies to the clinic. But innovation alone is…
A new publication by MSD in Organic Process Research & Development details the process development and large-scale manufacturing of the key Northern Fragment of Enlicitide Decanoate.
How can we help?
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA